 SAN DIEGO, April 05, 2021 GLOBE NEWSWIRE -- Otonomy, Inc. Nasdaq: OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 12 trial at the upcoming American Neurotology Societys 56th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting COSM, to be held virtually April 7-11, 2021. The oral presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose Throat Associates in Winston-Salem, North Carolina. Dr. Maxwell was an investigator in the trial. 